Ophthalmological manifestations in anti-neutrophil cytoplasmic antibodies associated vasculitis: retrospective analysis of 104 patients in a reference center in Argentina

  • Máximo Cosentino José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
  • Claudia Pena José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
  • María Victoria Martiré San Roque General Acute Interzonal Hospital, Gonnet, Province of Buenos Aires, Argentina
  • Lucila García José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
  • Mercedes García José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
Keywords: ANCA-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, ophthalmological manifestations

Abstract

Introduction: ophthalmological involvement (OI) in vasculitis associated with anti-neutrophil cytoplasmic antibodies (AAV) varies widely depending on the subtype of vasculitis. Objectives: to describe the frequency, clinical manifestations, and ophthalmological sequelae as well as factors associated with ophthalmological involvement in patients with ANCA-associated vasculitis (AAV). Materials and methods: a retrospective and analytical study in patients with AAV was performed. OI was recorded at the beginning of the disease, and patients were divided into two groups according to the presence or absence of OI. Descriptive statistics, bivariate and multivariate analysis were performed to evaluate the factors associated with OI. Results: one hundred and four patients with AAV were included, and 61.5% were women. Forty-nine percent of patients presented granulomatosis with polyangiitis (GPA), 34.6% microscopic polyangiitis (MPA), and 16.3% eosinophilic granulomatosis with polyangiitis (EGPA). Of the total, 30 patients (28.8%) presented OI at the beginning of the disease (47% GPA, 17.6% EGPA and 8.33% MPA). The orbital commitment was observed exclusively in patients with GPA. In the multivariate analysis, erythrosedimentation and thrombocytosis showed an association with OI. Ophthalmological sequelae were observed in 9 (30%) patients with OI. Conclusions: the frequency and clinical manifestations of OI depend on the type of AAV. Because the frequency and the possibility of subsequent sequelae are high, prompt identification and appropriate treatment are necessary.

Author Biographies

Máximo Cosentino, José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
Rheumatology Service
Claudia Pena, José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
Rheumatology Service
María Victoria Martiré, San Roque General Acute Interzonal Hospital, Gonnet, Province of Buenos Aires, Argentina
Rheumatology Service
Lucila García, José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
Rheumatology Service
Mercedes García, José San Martín Interzonal General Acute Hospital, La Plata, Province of Buenos Aires, Argentina
Rheumatology Service

References

I. Jannette JC. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol 2013 Oct; 17(5):603-606. doi: 10.1007/s10157-013-0869-6.

II. Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. AJKD 2020;75(1):124-137. doi: 10.1053/j.ajkd.2019.04.031.

III. Di Benedetto N, López-Mujica MX, Fernández ME, Touron M, Muñoz SA, Allievi A. Características generales de 29 pacientes con vasculitis de pequeños vasos. Medicina (Buenos Aires) 2010;70:127-132.

IV. Macarie SS, Mihaila RM, Macarie DM, Toc DA. Therapy of ocular complications in ANCA+ associated vasculitis. Romanian Journal of Ophthalmology 2021;65(1):10-14. doi:10.22336/rjo.2021.3

V. Pierini FS, Scolnik M, Scaglioni V, Mollerach F, Soriano E. Incidencia y prevalencia de granulomatosis con poliangeitis y poliangeitis microscópica en organizaciones de gestión de la salud en Argentina: un estudio de 15 años. Clin Reumatol 2019;38(7): 1935-1940. doi: 10.1007/s10067-019-04463-y.

VI. Pérez N, Gargiulo MA, Suarez L, Khoury M, Gómez G. Clinical characteristics and prognostic factors in an Argentinian cohort with anca-associated vasculitis. Medicina (Buenos Aires) 2021;81:198-207.

VII. Macarie SS, Kadar A. Eye involvement in ANCA positive vasculitis. Romanian Journal of Ophthalmology 2020;64(1):3-7.

VIII. Schmidt J, Pulido JS, Matteson EL. Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Current Opinion in Ophthalmology 2011;22:489-495. doi: 10.1097/ICU.0b013e32834bdfe2.

IX. Rothschild PR, Pagnoux C, Seror R, Brezin AP, Delair E, Guillevin L. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum 2013 Apr;42(5):507-14. doi: 10.1016/j.semarthrit.2012.08.00.

X. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6. doi:10.1002/art.1780330812.

XI. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994 Nov;87(11):671-8

XII. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011 Jan;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6.

XIII. Scaglioni V, Scolnik M, Marin J, Bravo M, Zacariaz JB, Catay ER, et al. Vasculitis de pequeños vasos asociadas a anticuerpos anticitoplasma de neutrofilos. Estudio clinico y sobrevida de una cohorte de 84 pacientes seguida en un único centro. Disponible en: https://www.hospitalitaliano.org.ar/multimedia/archivos/servicios_attachs/8717.pdf

XIV. Wang Y, Zhao M, Yu J, Xin G, Liu Y, Zhang Y, et al. The clinical and pathological characteristics of Chinese elderly patients with anti-neutrophil cytoplasmic autoantibodies associated small vessel vasculitis. Experimental Gerontology 2004;39:1401-1405. doi: 10.1016/j.exger.2004.05.004.

XV. Junek ML, Zhao L, Garner S, Cuthbertson D, Pagnoux C, Koening CL, et al. Ocular manifestations of ANCA-associated vasculitis. Rheumatology (Oxford) 2023 Jul 5;62(7):2517-2524. doi: 10.1093/rheumatology/keac663.

XVI. Pérez-Jacoiste Asín MA, Charles P, Rothschild P, Terrier B, Brézin A, Mouthon L, et al. Ocular involvement in granulomatosis with polyangiitis. A single-center cohort study on 63 patients. Autoimmunity Reviews 2019 May;18(5):493-500. doi: 10.1016/j.autrev.2019.03.001.

XVII. Kubaisi B, Abu Samra K, Foster CS. Granulomatosis with polyangiitis (Wegener's disease). An updated review of ocular disease manifestations. Intractable & Rare Diseases Research 2016 May;5(2):61-9. doi: 10.5582/irdr.2016.01014.

XVIII. Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular manifestations of granulomatosis with polyangiitis: a review of the literature. Ophthalmol Ther 2019 Jun;8(2):227-234. doi: 10.1007/s40123-019-0176-8.

XIX. Říhová E, Svozilkova P, Brichova M, Klimova A, Kuthan P, Diblik P. Ocular manifestations of granulomatosis with polyangiitis. Cesk Slov Oftalmol 2019 Spring;74(5):167-174. doi: 10.31348/2018/5/1.

XX. Ismailova DS, Novikov PI, Grusha YO, Abramova YV, Bulanov NM, Makarov EA, et al. The frequency of ophthalmologic manifestations of granulomatosis with polyangiitis (Wegener's) and their relationship to systemic diseases. Ter Arkh 2017;89(5):69-73. doi: 10.17116/terarkh201789569-73.

XXI. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of Internal Medicine 1992;116:488-498. doi: 10.7326/0003-4819-116-6-488.

XXII. Kubal AA, Pérez VL. Ocular manifestations of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010 Aug;36(3):573-86. doi: 10.1016/j.rdc.2010.05.005.

XXIII. Hara A, Ohta S, Takata M, Saito K, Torisaki M, Ishida Y, et al. Microscopic polyangiitis with ocular manifestations as the initial presenting sign. Am J Med Sci 2007 Oct;334(4):308-10. doi: 10.1097/MAJ.0b013e3180a5e8c6.

XXIV. Mihara M, Hayasaka S, Watanabe K, Kitagawa K, Hayasaka Y. Ocular manifestations in patients with microscopic polyangiitis. Eur J Ophthalmol 2005 Jan-Feb;15(1):138-42. doi: 10.1177/112067210501500124.

XXV. Atili A, Richter C, Bahn E, Rustenbeck HH, Schittkowski M. Ocular manifestations of Churg-Strauss-Syndrome: review article and case report. Ophthalmologe 2013 Nov;110(11):1051-7. doi: 10.1007/s00347-013-2815-0.

XXVI. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicina (Baltimore) 1999 Jan;78(1):26-37. doi: 10.1097/00005792-199901000-00003.

XXVII. Gheita TA, Abd El Latif EM. Relationship of ocular presentation in granulomatosis with polyangiitis to autoantibodies and disease activity. Z Rheumatol 2019 Apr;78(3):281-286. doi: 10.1007/s00393-018-0495-5.

Published
2024-06-11
How to Cite
1.
Cosentino M, Pena C, Martiré MV, García L, García M. Ophthalmological manifestations in anti-neutrophil cytoplasmic antibodies associated vasculitis: retrospective analysis of 104 patients in a reference center in Argentina. Rev. Argent. Reumatol. [Internet]. 2024Jun.11 [cited 2025Jan.21];35(2):23 -0. Available from: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/810
Section
Original Article